Related Experiment Video
Updated: Jun 26, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from
Ingar Holme1, Nilo B Cater, Ole Faergeman
1Center of Preventive Medicine, Ullevål University Hospital, Oslo, Norway.
Insights
Apolipoprotein B (apoB)/apoA-1 ratio best predicts coronary heart disease (CHD) events in patients on statins. ApoB and non-HDL-C best explain outcome differences between statin treatments, suggesting wider clinical use.
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Pharmacotherapy
Background:
- Limited research exists on apolipoprotein B (apoB) and apolipoprotein A-1 (apoA-1) efficacy in predicting new coronary heart disease (CHD) events in patients already undergoing statin therapy.
- Understanding the predictive value of specific lipoprotein components is crucial for refining risk assessment in CHD patients on lipid-lowering treatments.
Purpose of the Study:
- To compare the predictive capabilities of various lipoprotein components for CHD events within the IDEAL trial.
- To determine the extent to which differences in lipoprotein parameters explain observed treatment outcomes.
- To evaluate the effectiveness of atorvastatin versus simvastatin in preventing CHD events.
Main Methods:
- The IDEAL trial compared atorvastatin 80 mg/day to simvastatin 20-40 mg/day in patients with CHD.
- Cox regression models were employed to analyze the association between on-treatment levels of lipoprotein components and subsequent major coronary events (MCE).
- Predictive values of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apoB, and apoB/apoA-1 ratio were assessed.
Main Results:
- On-treatment apoB/apoA-1 ratio demonstrated the strongest association with MCE in the overall patient population.
- Non-HDL-C and apoB were more predictive than LDL-C for MCE.
- ApoB and non-HDL-C were the most effective predictors for explaining differences in risk reduction between the atorvastatin and simvastatin treatment groups.
Conclusions:
- The on-treatment apoB/apoA-1 ratio is a powerful predictor of major coronary events in patients with CHD on statin therapy.
- ApoB and non-HDL-C levels are key determinants of differential treatment outcomes between statin regimens.
- Increased availability of apoB and apoA-1 measurements is recommended for routine clinical risk assessment.
Background:
Few studies have looked into the ability of measurements of apolipoprotein B (apoB) and apolipoprotein A-1 (apoA-1) or apoB/apoA-1 to predict new coronary heart disease (CHD) events in patients with CHD on statin treatment.
Aims:
In the IDEAL trial, to compare lipoprotein components to predict CHD events and to what degree differences in those parameters could explain the observed outcome.
Methods:
We compared the ability of treatment with atorvastatin 80 mg/day to that of simvastatin 20-40 mg/day to prevent CHD events in patients with CHD and used Cox regression models to study the relationships between on-treatment levels of lipoprotein components to subsequent major coronary events (MCE).
Findings:
Variables related to low-density lipoprotein cholesterol (LDL-C) carried more predictive information than those related to high-density lipoprotein cholesterol (HDL-C), but LDL-C was less predictive than both non-HDL-C and apoB. The ratio of apoB to apoA-1 was most strongly related to MCE. However, for estimating differences in relative risk reduction between the treatment groups, apoB and non-HDL-C were the strongest predictors.
Interpretation:
The on-treatment level of apoB/apoA-1 was the strongest predictor of MCE in the pooled patient population, whereas apoB and non-HDL-C were best able to explain the difference in outcome between treatment groups. Measurements of apoB and apoA-1 should be more widely available for routine clinical assessments.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:26Coronary Artery Disease IV: Preventive Measures
01:29Pharmacogenomics: Identification of New Drug Targets
01:31Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...